Pioneering Innovation at AbbVie’s R&D Sites

AbbVie is headquartered in North Chicago, IL. Here, we take on some of the world's most complex diseases, focusing on immunology, oncology and neuroscience. Our headquarters covers the full spectrum of research and development from the initial idea to the finished product.

Our headquarters is also home to our drug discovery engine, which drives our existing and novel therapeutic platforms, and our Genomics Research Center, which translates genetic information into a more personalized approach to medicines. It’s also home to other areas of expertise, including regulatory affairs, patient safety, manufacturing, process chemistry, solid state chemistry, process engineering, medical affairs, and quality assurance.

Our Irvine site is home to our Center of Excellence for aesthetics, neurotoxins, neuro-psychiatry, migraine and eye care research. The 54-acre, 1,000,000-square-foot campus offers unique scientific expertise in the research and development of translational and pharmaceutical sciences to deliver patient-centric, innovative medicines.

The latest addition to our R&D locations, our Bay Area site is the epicenter of our cutting-edge work to advance oncology research. Here, we're evaluating a range of investigational medicines as potential treatments for various types of cancer and accelerating our R&D pipeline in immuno-oncology, tumor targeting, tumor dependencies and precision medicine. AbbVie Bay Area is also home to other functions including data statistics and analytics, medical affairs, patient safety, quality assurance and regulatory affairs.

This new 48,000-square-foot campus, located in the birthplace of biotech, opens doors to new partnerships and collaboration to advance the next breakthroughs.

AbbVie's Cambridge Research Center is a 43,000-square-foot facility located in the Cambridge, Massachusetts biotech corridor. Inside this research center, our scientists are focused on understanding the biological mechanisms underlying neurodegenerative diseases, in particular, Alzheimer's and Parkinson's diseases, as well as immune-mediated diseases.

For over 30 years, the AbbVie Bioresearch Center in Worcester, Massachusetts, has been an industry leader in drug discovery, development sciences and biologics research. This 553,000-square-foot facility focuses on biotherapeutics development and explores innovative solutions for some of the toughest challenges in medicine, including immunology and neuroscience.

At our integrated facility in Ludwigshafen, Germany, we carry out every step of drug research, development and production. Here, scientists look for ways to treat neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and pioneer new methods of formulating complex compounds to make better medicines possible.

Ludwigshafen also contributes to the digitalization of research by utilizing artificial intelligence, machine learning, bioinformatics and other technologies that enable preclinical and clinical studies worldwide.

AbbVie's Tokyo R&D site is home to our full clinical development capabilities. To obtain NDA approvals for AbbVie's products for Japanese patients, we conduct studies in parallel from phase 1 to phase 4. We perform strategic clinical planning functions for each focus area to develop the Japan-specific development strategy across oncology, immunology, neuroscience, specialty, eye care and aesthetics.